Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion

Q L Lu, G E Morris, S D Wilton, T Ly, O V Artem'yeva, P Strong, T A Partridge, Q L Lu, G E Morris, S D Wilton, T Ly, O V Artem'yeva, P Strong, T A Partridge

Abstract

Conventionally, nonsense mutations within a gene preclude synthesis of a full-length functional protein. Obviation of such a blockage is seen in the mdx mouse, where despite a nonsense mutation in exon 23 of the dystrophin gene, occasional so-called revertant muscle fibers are seen to contain near-normal levels of its protein product. Here, we show that reversion of dystrophin expression in mdx mice muscle involves unprecedented massive loss of up to 30 exons. We detected several alternatively processed transcripts that could account for some of the revertant dystrophins and could not detect genomic deletion from the region commonly skipped in revertant dystrophin. This, together with exon skipping in two noncontiguous regions, favors aberrant splicing as the mechanism for the restoration of dystrophin, but is hard to reconcile with the clonal idiosyncrasy of revertant dystrophins. Revertant dystrophins retain functional domains and mediate plasmalemmal assembly of the dystrophin-associated glycoprotein complex. Physiological function of revertant fibers is demonstrated by the clonal growth of revertant clusters with age, suggesting that revertant dystrophin could be used as a guide to the construction of dystrophin expression vectors for individual gene therapy. The dystrophin gene in the mdx mouse provides a favored system for study of exon skipping associated with nonsense mutations.

Figures

Figure 1
Figure 1
Age-related expansion of RF in mdx mouse muscles. (A) New born, (B) 4 wk, (C) 4 mo, and (D) 18 mo. The size of RF clusters increases from isolated single fibers in the new born mouse to a huge cluster containing >60 RFs in the 18-mo-old mouse. Variation of RFs in size and of staining intensity within a cluster is seen in mice aged 4 wk or older. Sections are stained for dystrophin with polyclonal antibody p6.
Figure 3
Figure 3
Expression of dystrophin and dystrophin-associated glycoprotein complex in RFs. A group of fibers are stained with p6 for dystrophin. The same group of fibers are clearly stained for β-dystroglycan, α- and β-sarcoglycan, and α-syntrophin and the staining intensity is correlated to that of dystrophin. The remaining fibers are only weakly or not stained for the Abs. All fibers are stained for spectrin (bottom left panel). Serial sections of TE muscle from 18-mo-old mdx mouse.
Figure 2
Figure 2
An overall age-related increase of RFs in TE muscle of mdx mouse. The number and length of RF clusters and maximum number of RFs within one cluster increase steadily, resulting in a huge increase in the number of RF sections within 1,000 μm of TE muscles. NB, new born mice; W, weeks; M, months; and Maxi No, maximum number. Vertical bars represent standard deviation. The total number of RFs counted in all 100 sections was referred to as RF sections.
Figure 5
Figure 5
Patterns of epitope loss in RF. Total of 279 RF clusters were examined with 14 Abs to dystrophin by three-step immunoperoxidase staining. Loss of 20 exons or more was found in >65% of RF clusters.
Figure 4
Figure 4
Exon mapping of RF. Staining of serial sections with a panel of 12 Abs (name above and exon specificity below the pictures). Sections are arranged in such an order from left to right with Ab recognizing exons from NH2-terminal to COOH-terminal. The diagram below illustrates the position of the epitope(s) recognized by the Abs on the dystrophin molecule. Serial number of sections appears at the bottom right corners. Two isolated fiber clusters marked a and b with two and one fibers, respectively. Fibers a are recognized by Abs to NH2-terminal exons up to 18, but negative with Abs to exons 20–26. These fibers are positive with Ab to exons 27–28, but negative again with Abs to exons from 26–29 to 38–39 followed by relatively weak staining with Ab to exons 40–41. Fiber b is recognized by Abs to NH2-terminal exons up to 27–28, with relatively weak staining with Abs to exons 20–21. This fiber is not recognized with Ab against exons 26–29 to 38–39. Another revertant fiber of small caliber stained with Abs to exons 26–29 and 50 appears at the bottom of the sections, which are at the end of this serial sections. The primary Abs were detected with peroxidase method and the pictures are presented as negative image to enhance contrast. Nuclei appear positive due to the haematoxylin counterstaining.
Figure 7
Figure 7
Combined immunohistochemistry and in situ hybridization for detection of dystrophin protein and genomic sequence of intron 21 to exon 25. Dystrophin protein in RFs is stained with immunoperoxidase method and the positive staining is shown as false green color. Hybridization signals for the genomic region of dystrophin sequences are shown as false red color. Nuclei are counterstained with 4,6-diamidino-2-phenylindole (DAPI), showing as blue. Sections are first stained with antibody p6 for dystrophin on unfixed sections followed by in situ hybridization.

References

    1. Allen D.L., Roy R.R., Edgerton V.R. Myonuclear domain in muscle adaptation and disease. Muscle Nerve. 1999;22:1350–1360.
    1. Amalfitano A., Rafael J.A., Chamberlain J.S. Structure and mutation of the dystrophin gene. In: Brown S.C., Lucy-Jack A., editors. Dystrophin Gene, Protein and Cell Biology. Cambridge University Press; Cambridge, UK: 1997. pp. 1–26.
    1. Baylies M.K., Bate M., Ruiz Gomez M. Myogenesisa view from Drosophila . Cell. 1998;93:921–927.
    1. Bies R.D., Phelps S.F., Cortez M.D., Roberts R., Caskey C.T., Chamberlain J.S. Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res. 1992;20:1725–1731.
    1. Bockhold K.J., Rosenblatt J.D., Partridge T.A. Aging normal and dystrophic mouse muscleanalysis of myogenicity in cultures of living single fibers. Muscle Nerve. 1998;21:173–183.
    1. Blaveri K., Heslop L., Yu D.S., Rosenblatt J.D., Gross J.G., Partridge T.A., Morgan J.E. Patterns of repair of dystrophic mouse musclestudies on isolated fibers. Dev. Dyn. 1999;216:244–256.
    1. Breitbart R.E., Nadal-Ginard B. Developmental induced, muscle specific trans factors control the differential splicing of alternative and constitutive troponin-T exons. Cell. 1987;49:793–803.
    1. Bulfield G., Siller W.G., Wright P.A.L., Moore K.J. X chromosome linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA. 1984;81:1189–1192.
    1. Burrow K.L., Coovert D.D., Klein C.J., Bulman D.E., Kissel J.T., Rammohan K.W., Burghes A.H.M., Mendell J.R. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Neurology. 1991;41:661–666.
    1. Chelly J., Gilgenkrantz H., Lambert M., Hamard G., Chafey P., Recan D., Katz P., de la Chapelle A., Koenig M., Ginjaar I.B. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell. 1990;63:1239–1248.
    1. Darling T.N., Yee C., Bauer J.W., Hintner H., Yancey K.B. Revertant mosaicismpartial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J. Clin. Invest. 1999;103:1371–1377.
    1. Dietz H.C., Valle D., Francomano C.A., Kendzior R.J., Jr., Pyeritz R.E., Cutting G.R. The skipping of constitutive exons in vivo induced by nonsense mutations. Science. 1993;259:680–683.
    1. Dunckley M.G., Wells D.J., Walsh F.S., Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum. Mol. Genet. 1993;2:717–723.
    1. Ellis J.M., Man N.T., Morris G.E., Ginjaar I.B., Moorman A.F.M., van Omen G.J.B. Specificity of dystrophin analysis improved with monoclonal antibodies. Lancet. 1990;336:881–882.
    1. Endo F., Awata H., Katoh H., Matsuda I. A nonsense mutation in the 4-hydroxyphenylpyruvic acid dioxygenase (Hpd) causes skipping of the constitutive exon and hypertyosinemia in mouse strain III. Genomics. 1995;25:164–169.
    1. Fanin M., Dnieli G.A., Cadaldini M., Miorin M., Vitiello L., Angelini C. Dystrophin-positive fibers in Duchenne dystrophyorigin and correlation to clinical course. Muscle Nerve. 1995;18:1115–1120.
    1. Feener C.A., Koenig M., Kunkel L.M. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature. 1989;338:509–511.
    1. Fisher C.W., Fisher C.R., Chuang J.L., Lau K.S., Chuang D.T., Cox R.P. Occurrence of a 2-bp (AT) deletion allele and a nonsense (G-to-T) mutant allele at the E2 (DBT) locus of six patients with maple syrup urine diseasemultiple-exon skipping as a secondary effect of the mutations. Am. J. Hum. Genet. 1993;52:414–424.
    1. Gibson R.A., Hajiampour A., Murer-Orlando M., Buchwald M., Mathew C.G. A nonsense mutation and exon skipping in the Fanconianaemia group C gene. Hum. Mol. Genet. 1993;2:797–799.
    1. Hoffman, E.P. 1993. Genotype/phenotype correlations in Duchenne/Becker dystrophy. Molecular and Cell Biology of Muscular Dystrophy. T. Partridge, editor. Chapman & Hall. 12–36.
    1. Hoffman E.P., Brown R.H., Jr., Kunkel L.M. Dystrophinthe protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928.
    1. Hoffman E.P., Morgan J.E., Watkins S.C., Partridge T.A. Somatic reversion/suppression of the mouse phenotype in vivo. J. Neurol. Sci. 1990;99:9–25.
    1. Kelly A.M., Rubinstein N.A. The diversity of muscle fiber types and its origin during development. In: Engel A.D., Franzini-Armstrong C., editors. MyologyBasic and Clinical. 2nd ed. McGraw-Hill, Inc.; New York: 1994. pp. 119–133.
    1. Klein C.J., Coovert D.D., Bulman D.E., Ray P.N., Mendell J.R., Burghes A.H.M. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD)evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 1992;50:950–959.
    1. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509–517.
    1. Lin C.L., Bristol L.A., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., Rothstein J.D. Aberrant RNA processing in a neurodegenerative diseasethe cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589–602.
    1. Love D.R., Flint T.J., Genet S.A., Middleton-Price H.R., Davies K.E. Becker muscular dystrophy patient with a large intragenic dystrophin deletionimplications for functional minigenes and gene therapy. J. Med. Genet. 1991;28:860–864.
    1. Lu Q.L., Dover R. Computer assisted signal co-localization for simultaneous detection of antigen by immunohistochemistry and DNA by non-isotopic in situ hybridization. Histochemistry. 1993;99:23–27.
    1. Lu Q.L., Partridge T.A. A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J. Histochem. Cytochem. 1998;46:977–983.
    1. Melis M.A., Montoni F., Cau M., Loi D., Puddu A., Boccone L., Mateddu A., Cianchetti C., Cao A. Novel nonsense mutation (C→A nt 10512) in exon 72 of the dystrophin gene leading to exon skipping in a patient with mild dystrophinopathy. Hum. Mutat. 1998;Suppl. 1):S137–S138.
    1. Mirabella M., Galluzzi G., Manfredi G., Bertini E., Ricci E., Deleo R., Tonali P., Servidei S. Giant dystrophin deletion associated with congenital cataract and milder muscular dystrophy. Neurology. 1998;51:592–595.
    1. Morris G.E., Nguyen C., Nguyen T.M. Specificity and VH sequence of two monoclonal antibodies against the N-terminus of dystrophin. Biochem. J. 1995;309:355–359.
    1. Naylor J.A., Green P.M., Rizza C.R., Giannelli F. Analysis of factor VIII mRNA defects in everyone of 28 haemophilia A patients. Hum. Mol. Genet. 1993;2:11–17.
    1. Nguyen T.M., Morris G.E. Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am. J. Hum. Genet. 1993;52:1057–1066.
    1. Nguyen T.M., Ellis J.M., Ginjaar I.B., van Paassen M.M., van Ommen G.J., Moorman A.F., Cartwright A.J., Morris G.E. Monoclonal antibody evidence for structural similarities between the central rod regions of actinin and dystrophin. FEBS Lett. 1990;272:109–112.
    1. Nicholson L.V.B., Davison K., Falkous G., Harwood C., O'Donnell E., Slater C.R., Harris J.B. Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibody. J. Neurol. Sci. 1989;94:125–136.
    1. Nicholson L.V.B., Johnson M.A., Bushby K.M.D., Gardner-Medwin D. Functional significance of dystrophin positive fibers in Duchenne muscular dystrophy. Arch. Dis. Child. 1993;68:632–636.
    1. Nishioka Y. Application of Y chromosomal repetitive sequences to sexing mouse embryos. Teratology. 1988;38:181–185.
    1. Partridge T.A., Morgan J.E., Pagel C.N., Coulton G.R., Skynner M.F., Coleman M., Watt D.J. Myoblast transplantation. In: Kakulas B.A., McChowell J., Roses A.D., editors. Duchenne Muscular DystrophyAnimal Models and Genetic Manipulation. Raven Press; New York: 1992. pp. 175–187.
    1. Pie J., Casals N., Casale C.H., Buesa C., Mascaro C., Barcelo A., Rolland M.O., Zabot T., Haro D., Eyskens F. A nonsense mutation in the 3-hydroxy-3-methylglutaryl-CoA lyase gene produces exon skipping in two patients of different origin with 3-hydroxy-3-methylglutaryl-CoA lyase dificiency. Biochem. J. 1997;323:329–335.
    1. Reed R., Maniatis T. Intron sequences involved in lariat formation during pre-mRNA splicing. Cell. 1985;41:95–105.
    1. Reiss J., Rininsland F. An explanation for the constitutive exon 9 cassette splicing of the DMD gene. Hum. Mol. Genet. 1994;3:295–298.
    1. Rushton E., Drysdale R., Abmayr S.M., Michelson A.M., Bate M. Mutations in a novel gene, myoblast city, provide evidence in support of the founder cell hypothesis for Drosophila muscle development. Development. 1995;121:1979–1988.
    1. Sedgwick S.G., Nguyen T.M., Ellis J.M., Crowne H., Morris G.E. Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin. Nucleic Acids Res. 1991;19:5889–5894.
    1. Sherratt T.G., Vulliamy T., Strong P.N. Evolutionary conservation of the dystrophin central rod domain. Biochem. J. 1992;287:755–759.
    1. Shiga N., Takeshima Y., Sakamoto H., Inoue K., Yokata Y., Yokoyama M., Masafumi M. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J. Clin. Invest. 1997;100:2204–2210.
    1. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., Barnard P.J. The molecular basis of muscular dystrophy in the mdx mousea point mutation. Science. 1989;244:1578–1579.
    1. Smith C.W.J., Patton J.G., Nadal-Ginard B. Alternative splicing in the control of gene expression. Annu. Rev. Genet. 1989;23:527–577.
    1. Strehler E.E., Periasamy M., Strehler-Page M.E., Nadal-Ginard B. Myosin light chain 1 and 3 gene has two structural distinct and differentially regulated promotors evolving at different rates. Mol. Cell. Biol. 1985;5:3168–3182.
    1. Thanh L.T., Nguyen T.M., Helliwell T.R., Morris G.E. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 1995;56:725–731.
    1. Tinsley J., Deconinck N., Fisher R., Kahn D., Phelps S., Gillis J.M., Davies K. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 1998;4:1441–1444.
    1. Uchino M., Tokunaga M., Mita S., Uyama E., Ando Y., Teramoto H., Miike T., Ando M. PCR and immunocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy. J. Neurol. Sci. 1995;129:44–50.
    1. Wieczorek D., Smith C.W.J., Nadal-Ginard B. The rat a-tropomyosin gene generates a minimum of six different mRNAs coding for straited smooth and non-muscle isoforms by alternative splicing. Mol. Cell. Biol. 1988;8:679–694.
    1. Wilton S.D., Dye D.E., Lainy N.G. Dystrophin gene transcripts skipping the mdx mutation Muscle Nerve. 20 1997. 728 734a
    1. Wilton S.D., Lim L., Dye D.E., Lainy N.G. A PCR-based alternative to cloning PCR products Biotechniques. 22 1997. 642 645b
    1. Wilton S.D., Lloyd F., Carville K., Fletcher S., Honeyman K., Agrawal S., Kole R. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord. 1999;9:330–338.
    1. Winder S.J., Knight A.E., Kendrick-Jones J. Protein structure. In: Brown S.C., Lucy-Jack A., editors. Dystrophin Gene, Protein and Cell Biology. Cambridge University Press; Cambridge, UK: 1997. pp. 27–55.
    1. Winnard A.V., Klein C.J., Coovert D.D., Prior T., Papp A., Snyder P., Bulman D.E., Ray P.N., McAndrew P., King W. Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum. Mol. Genet. 1993;2:737–744.
    1. Winnard A.V., Mendell J.R., Prior T.W., Florence J., Burghes A.H. Frameshift deletion of exons 3-7 and revertant fibers in Duchenne muscular dystrophymechanisms of dystrophin production. Am. J. Hum. Genet. 1995;56:158–166.
    1. Zatz M., Sumita D., Campiotto S., Canovas M., Cerquueiva A., Vainzof M., Passos-Bueno M.R. Paternal inheritance or different mutations in maternally related patients occur in about 3% Duchenne familial cases. Am. J. Med. Genet. 1998;78:361–365.

Source: PubMed

3
S'abonner